TORONTO – October 31, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has enlisted Emmy Award-winning broadcaster Montel Williams for its next Let's Huddle patient webinar on November 5, 2026, at 3:00 p.m. ET, extending the reach of its prostate care outreach program.

TORONTO – October 31, 2026 -- Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) has signed a supply and distribution agreement with the iMRI Division of Cook Medical, adding a second U.S. capital equipment channel for its TULSA-PRO system while keeping recurring treatment kit and service revenue in-house.

TORONTO – October 14, 2026 -- Patients treated with whole-gland TULSA were more than twice as likely to preserve both erectile function and pad-free continence at six months as those who had robotic radical prostatectomy (risk ratio 2.1; p=0.004), according to CAPTAIN trial data. Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) presented the results among five abstracts at the 15th Interventional MRI Symposium in Boston.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) will report its second quarter 2026 financial results after market close on Thursday, August 6, 2026.

Management hosts call at 4:30 p.m. ET on results day

The interventional MRI (iMRI) company will hold a conference call at 4:30 p.m. ET on August 6 to review the quarter's results and discuss business developments in the period. Investors must register in advance for the live call.

Toronto – October 12, 2026 -- Men treated with whole-gland TULSA Procedure showed no median change in penile length at one month, compared with a median 0.65 cm reduction after robotic radical prostatectomy (RP), according to new data from the Level 1 CAPTAIN randomized controlled trial, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) cut its second-quarter 2026 net loss 39% to about $9.5 million, or $0.26 per share, from $15.7 million, or $0.52 per share, a year earlier. Operating expenses fell 16% to about $13.0 million, and the company reiterated its full-year revenue guidance of about $25.0 million.

Toronto – – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) replaced its chief financial officer effective immediately, promoting Corporate Controller Matthew Sobczyk to Interim CFO after Rashed Dewan stepped down from the role.

Sobczyk, a 2020 hire, takes over the finance function

Sobczyk first joined the interventional MRI (iMRI) company in 2020 and moves up from Corporate Controller. The company did not name a permanent successor or give a timeline for a CFO search.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has introduced new Treatment Delivery Console (TDC) software that it says provides a roadmap for surgeons to perform up to six TULSA Procedures per system per day, up from a reported maximum of four among a few physicians today.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has appointed Richard Fabian, a medical imaging executive with more than 29 years of experience, as President, effective immediately, as the company moves its previous President into a newly created Chief Technology Officer role.